ZBIOZenas BioPharma, Inc.
What is the market doing?
No clear lean: nothing decisive, though a crowded short (+21% of shares).
Choppy, but holding above its 200-day average. Price is +6% vs its 200-day average.
A crowded short, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How ZBIO is trading
Zenas BioPharma, Inc. is +44% over the past year while the S&P 500 is +18%: 26 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +6.3%
vs 200-day average · close to trend
- RSI (14)
- 32
RSI (14) · neutral
- Below its 52-week high
- 37%
Below its 52-week high
Details›
- Last close2026-10-09
- $27.24
- 1 monthS&P 500 +2.7%
- −12%
- 1 yearS&P 500 +18%
- +44%
- vs 50-day average$30.80
- −12%
- 52-week high
- $43.17
- 52-week low
- $15.20
- Annualised volatility
- 104%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- $2.1M
| Year | Return |
|---|---|
| 2026 (year to date) | −25% |
| 2025 | +343% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 2 | 0 of 2 | −26% |
| Feb | 2 | 1 of 2 | +15% |
| Mar | 2 | 1 of 2 | −6.6% |
| Apr | 2 | 1 of 2 | +23% |
| May | 2 | 0 of 2 | −11% |
| Jun | 2 | 2 of 2 | +18% |
| Jul | 2 | 2 of 2 | +47% |
| Aug | 2 | 1 of 2 | +0.83% |
| Sep | 2 | 1 of 2 | +11% |
| Oct | 3 | 3 of 3 | +22% |
| Nov | 2 | 1 of 2 | −11% |
| Dec | 2 | 0 of 2 | −18% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Biotechnology
The closest names by size in the same industry